Study Showed High Accuracy in Determining
Amyloid Burden Across All Stages of Alzheimer's Disease
Progression, Supporting Early Detection, Treatment, Interventions
and Tracking
ALZpath pTau217 Antibody Has Now Been Utilized
in Over 40 Cohort Studies with 50,000 Samples
CARLSBAD, Calif., July 29,
2024 /PRNewswire/ -- ALZpath, Inc., a leading
developer of innovative diagnostic tools and solutions for
Alzheimer's disease and related dementias, announced today the
results of a multi-cohort study, evaluating the performance,
cross-assay comparison and clinical launch of the ALZpath pTau217
antibody for use in blood-based tests to identify Alzheimer's
disease pathology. The study results will be presented today in a
Featured Research Session at the Alzheimer's Association
International Conference (AAIC) in Philadelphia.
Alzheimer's disease and related dementias affect 55 million
people worldwide, with projections nearly 140 million by 2050.
Despite its prevalence, nearly 75% of patients, including millions
with Alzheimer's disease, remain undiagnosed, depriving them access
to clinical trials, new disease-modifying therapies (DMTs) and
specialized care.
The ALZpath pTau217 antibody is designed to power the most
advanced, highly sensitive blood tests for Alzheimer's disease and
related dementias used globally by researchers, clinicians,
diagnostics companies and industry partners. Most recently, ALZpath
announced licensing deals for use of its proprietary pTau217
antibody in vitro diagnostic (IVD) tests being developed by
Roche and Beckman Coulter.
"The ALZpath pTau217 antibody enters the market at a critical
time for the industry as DMTs become more accessible, supporting
timely identification, intervention, clinical trial initiation and
facilitation of breakthrough treatments," said Chad Holland, CEO of ALZpath. "Traditional
diagnostic methods today – positron emission tomography (PET)
imaging and analysis of cerebral spinal fluid (CSF) obtained via
lumbar puncture - are invasive, costly, and limited in
availability. The need for accurate and convenient testing methods,
such as blood tests, has never been more evident."
The ALZpath pTau217 antibody is the first commercially available
antibody shown to reliably and accurately predict amyloid and tau
burden when integrated into advanced blood-based tests available
across a variety of platforms. The findings demonstrated that
assays incorporating the proprietary ALZpath antibody had the
strongest alignment with amyloid load, as measured by PET imaging,
in a population of healthy and MCI individuals in comparison with
other blood-based AD biomarker assessments, including the
integration of multiple biomarkers.
"The study highlights the importance of efforts underway to
develop a pTau217 reference standard," said Sterling Johnson, PhD, co-author of the study
and presenter of research at AAIC. "The high accuracy exhibited in
assays incorporating the ALZpath pTau217 antibody in predicting
amyloid and tau burdens across various stages of the Alzheimer's
disease continuum supports the use of convenient and scalable blood
tests utilizing ALZpath's antibody, to enable early identification
of the disease and improved care outcomes."
ALZpath will be participating in 37 presentations at AAIC.
Details for the Featured Research Session can be found below:
Session #86683
Monday, July 29, 2024
9:00 AM – 10:30 AM EDT
Pennsylvania Convention Center
118 ABC
About ALZpath
ALZpath is a leading developer of
innovative diagnostic tools and solutions for Alzheimer's disease
and related dementias. The novel ALZpath pTau217 antibody, integral
to the most advanced, widely available blood-based tests to detect
Alzheimer's disease, is transforming its diagnosis and treatment
monitoring, providing accurate and accessible tools for researchers
and healthcare professionals worldwide. To help millions of
patients in need, ALZpath democratizes access to its proprietary
robust antibody, which is used by researchers, clinicians, and
industry partners around the world to accelerate the discovery of
new treatments and improve patient care.
To learn more about the company, please visit
https://alzpath.bio/ and follow us on LinkedIn.
ALZpath Media Contact:
Nechama
Rosengarten
FINN Partners
nechama.rosengarten@finnpartners.com
View original
content:https://www.prnewswire.com/news-releases/new-data-presented-at-aaic-2024-demonstrates-high-accuracy-of-blood-tests-incorporating-alzpath-proprietary-ptau217-antibody-for-alzheimers-disease-diagnosis-302208587.html
SOURCE ALZpath, Inc.